palmitoylethanolamide.com.au
HomeResearchLorenzo 2015

Delay of morphine tolerance by palmitoylethanolamide

Lorenzo Di Cesare Mannelli, Francesca Corti, Laura Micheli, Matteo Zanardelli, Carla Ghelardini. Biomed Res Int. 2015;2015:894732.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Rats given daily morphine to induce tolerance
Dose used in the study
PEA, 30 mg/kg given under the skin daily, alongside morphine 10 mg/kg given into the abdomen daily
Duration
Daily dosing tracked over multiple days until tolerance developed
What was measured
Days of continued morphine pain-relief efficacy, microglia and astrocyte cell counts in the spinal dorsal horn, and TNF-alpha levels and immunoreactivity in astrocytes

What the authors reported

PEA roughly doubled the number of days morphine remained effective compared with morphine alone. It prevented the increase in microglia and astrocyte numbers that morphine caused in the spinal cord, but did not change the rise in spinal TNF-alpha levels, though TNF-alpha immunoreactivity within astrocytes was higher in PEA-treated rats.

Limits of this study

A rat model of morphine tolerance; it cannot show effect in people using opioids for pain. Funding and conflicts not stated in the abstract.

Source

PubMed 25874232 · doi:10.1155/2015/894732

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.